Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider No. 16669, for 8.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Jazz Pharmaceuticals, Inc, and Kite, a Gilead Company.

2nd Annual Live Medical Crossfire®: Hematologic Malignancies Online


Release Date: September 28, 2018
Expiration Date: September 28, 2019
Media: Internet - based

Activity Overview

The 2nd Annual Live Medical Crossfire®: Hematologic Malignancies was a live, full-day version of the renowned Medical Crossfire® format. This 1-day conference was developed to allow you to explore many of the most hotly debated clinical issues in the management of hematologic malignancies. Furthermore, this meeting was designed to facilitate the practical application of emerging data key to treating a broad range of hematologic malignancies, providing you with the information you need to confidently make personalized clinical decisions for your patients and apply novel strategies to real-world clinical case scenarios you routinely encounter in your practice.

For the Live Medical Crossfire®, we assembled renowned experts in the management of leukemias, lymphomas, and myeloma to facilitate discussion both among the faculty and with you in the audience. The program format for this meeting was unique. Each tumor’s section began with a brief evidence-based assessment of the evolving therapeutic space and transitioned quickly to the accompanying clinical questions that were the focus of the expert crossfire session. Each section concluded with a crossfire from the live audience at the meeting.

This online activity captures all the lectures presented at the 2018 2nd Annual Live Medical Crossfire®: Hematologic Malignancies and organizes them in a convenient modular format.
 

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Jazz Pharmaceuticals, Inc, and Kite, a Gilead Company.

 

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward hematologists and medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, investigators, and other health care professionals interested in the treatment of cancer will be invited to participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  • Appraise testing strategies that may inform clinical decision making in the management of hematologic malignancies
  • Apply clinical trial results to multiple lines of care in the management of hematologic malignancies
  • Analyze disparities in care for patients with hematologic malignancies
  • Outline strategies to monitor and proactively manage treatment-related toxicities in patients with leukemia, lymphoma, and multiple myeloma
  • Identify key emerging data pertaining to the diagnosis and management of patients with hematologic malignancies

Faculty, Staff, and Planners' Disclosures

 

CHAIR

Anas Younes, MD
Professor of Medicine and Chief of Lymphoma Service
Department of Medicine
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Novartis, Johnson & Johnson, Curis, Roche, Bristol-Myers Squibb Consultant: Bayer, Bristol-Myers Squibb, Celgene, Incyte, Janssen, Sanofi, Seattle Genetics, Takeda Millennium, Genentech, Merck

FACULTY

Jane Apperley, MBChB, MD, FRCP, FRCPath
Faculty of Medicine
Department of Medicine
Imperial College London
London, United Kingdom
 

Disclosures: Research Support: Ariad, Pfizer; Consultant: Incyte, Novartis, Pfizer, Takeda, Therakos; Speakers’ Bureau: Bristol-Myers Squibb, Incyte, Novartis, Pfizer, Therakos

Jacqueline Barrientos, MD, MS
Associate Professor
Division of Hematology and Medical Oncology
Department of Medicine
Hofstra/Northwell School of Medicine
Hempstead, NY

Disclosures: Grant Research Support: Gilead, Pharmacyclics/AbbVie, Acerta, American Society of Hematology/Harold Amos Medical Faculty Development Program; Consultant: Gilead, Pharmacyclics/AbbVie

Noa Biran, MD
Multiple Myeloma Division
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, NJ
 
 

Disclosures: Grant Research Support: Merck, Bristol-Myers Squibb; Consultant: Takeda, Celgene, Amgen; Speakers’ Bureau: Takeda, Celgene, Amgen, Sanofi, Janssen

Danielle M. Brander, MD
Assistant Professor of Medicine
Duke Cancer Institute
Duke University Health System
Durham, NC
 

Disclosures: Consultant: AbbVie, Teva, Pharmacyclics, Genentech, TG Therapeutics; Other: Data and Safety Monitoring Board for Novartis

Robert W. Chen, MD
Associate Professor of Medicine
City of Hope Medical Center
Duarte, CA
 
 

Disclosures: Grant Research Support: Seattle Genetics, Pharmacyclics, Bristol-Myers Squibb; Consultant: Seattle Genetics, Pharmacyclics, Bristol-Myers Squibb, Merck; Speakers’ Bureau: Seattle Genetics, Genentech, Merck

Graham Collins, MD, DPhil
Consultant Hematologist
Oxford University Hospitals
Oxford, United Kingdom
 
 

Disclosures: Grant Research Support: Amgen, Celgene, MSD, Celleron; Consultant: Roche, Takeda, Bristol-Myers Squibb, MSD, Celeron, Gilead; Speakers’ Bureau: Roche, Takeda, Bristol-Myers Squibb

Naval G. Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Bristol-Myers Squibb, Pfizer, Merck, Incyte, Sunesis, Kiromic, Karyopharm, Daiichi-Sankyo; Consultant: Otsuka, Pfizer, Incyte, Alexion, Sunesis, Karyopharm, ImmunoGen, Bristol-Myers Squibb

Daniel J. DeAngelo, MD, PhD
Associate Professor of Medicine
Harvard Medical School Institute
Institute Physician
Adult Leukemia Program
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant Research Support: GlycoMimetics/Blueprint; Consultant: Amgen, Pfizer, Novartis, Incyte, Takeda, Shire

Gabriela Hobbs, MD
Instructor in Medicine
Massachusetts General Hospital
Boston, MA
 
 

Disclosures: Grant Research Support: Incyte, Bayer support research trials; Consultant: Celgene Ad Board

Elias Jabbour, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosures: No relevant financial relationships with commercial interests to disclose.

Neil E. Kay, MD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, MN
 

Disclosures: Grant Research Support: Pharmacyclics, Tolero, Acerta; Other: Data and Safety Monitoring Board for Gilead, MorphoSys, Infinity Pharm, Agios Pharm, Celgene and CytomX Therapeutics

Alexander M. Lesokhin, MD
Assistant Attending Physician
Memorial Sloan Kettering Cancer Institute
New York, NY
 
 

Disclosures: No relevant financial relationships with commercial interests to disclose.

Selina Luger, MD
Professor of Medicine
Director, Leukemia Program
Abramson Cancer Center
Perelman School of Medicine, University of Pennsylvania
Philadelphia, PA

Disclosures: Grant Research Support: Ariad, Cyclacel, Seattle Genetics, Onconova, Celgene; Consultant: Incyte, Pfizer, Astellas

Deepu Madduri, MD
Assistant Professor of Medicine
Division of Hematology and Oncology
The Tisch Cancer Institute
New York, NY
 

Disclosures: No relevant financial relationships with commercial interests to disclose.

Sham Mailankody, MBBS
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY
 
 

Disclosures: Grant Research Support: Clinical investigator on trials supported by Juno Therapeutics, Janssen, and Takeda Oncology

David Maloney, MD, PhD
Member, Clinical Research Division
Medical Director, Cellular Immunotherapy
Leonard and Norma Klorfine Endowed Chair for Clinical Research
Fred Hutchinson Cancer Research Center
Professor of Medicine, Division of Oncology
University of Washington
Seattle, WA

Disclosures: Grant Research Support: Juno Therapeutics and Kite Pharma, paid to my institution; Consultant: Kite Pharma, Novartis, Eureka Therapeutics, Genentech; Other: Data and Safety Monitoring Board for BioLineRX and Celgene

Anthony Mato, MD, MSCE
Director, CLL Program
Memorial Sloan Kettering Cancer Center
New York, NY
 
 

Disclosures: Grant Research Support: TG Therapeutics, Gilead, Pharmacyclics, Regeneron, AbbVie, Portola, Acerta; Consultant: Celgene, Gilead, AbbVie, TG Therapeutics

Michael J. Mauro, MD
Leader, Myeloproliferative Neoplasms Program
Attending Physician, Leukemia Service Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, NY

Disclosures: Grant Research Support: Novartis Oncology; Consultant: Novartis Oncology, Bristol-Myers Squibb, Pfizer, Ariad

Bruno C. Medeiros, MD
Associate Professor of Medicine (Hematology)
Stanford University Medical Center
Stanford, CA
 
 

Disclosures: Grant Research Support: Jazz, Novartis, Celgene, Astellas; Consultant: Jazz, Novartis, Celgene, Astellas

Sattva S. Neelapu, MD
Professor and Deputy Chair ad interim
Department of Lymphoma and Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosures: Grant Research Support: Kite Pharma, Merck, Bristol-Myers Squibb, Cellectis, Poseida; Consultant: Kite/Gilead, Novartis, Merck, Celgene, Unum Therapeutics; Other: Participation in advisory or review activities (Kite Pharma, Merck, Celgene)

Ruben Niesvizky, MD
Professor of Medicine
Director, Oncology Operations
Weill Cornell Medical Center/NewYork-Presbyterian Hospital
Director, Multiple Myeloma Center
New York, NY

Disclosures: Consultant: Celgene, Amgen, Takeda Pharmaceuticals, Janssen, Bristol-Myers Squibb

Javier Pinilla-Ibarz, MD, PhD
Senior Member
Lymphoma Section Head and Director of Immunotherapy
Malignant Hematology Department
H. Lee Moffitt Cancer Center & Research Institute
Tampa, FL

Disclosures: Consultant: Janssen, Pharmacyclics, Gilead, AbbVie, Novartis, Pfizer; Speakers’ Bureau: AbbVie, Gilead, Pharmacyclics, Takeda

Daniel A. Pollyea, MD, MS
Associate Professor
Clinical Director, Leukemia Services
Division of Hematology
University of Colorado Cancer Center
University of Colorado School of Medicine
Aurora, CO

Disclosures: Grant Research Support: Pfizer, Agios; Consultant: Celgene, Pfizer, Argenx, Agios, AbbVie, Celyad

Stephen J. Schuster, MD
Director, Lymphoma Program
Robert and Margarita Louis-Dreyfus Professor of Chronic Lymphocytic Leukemia and Lymphoma
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA

Disclosures: Grant Research Support: Novartis, Celgene, Merck, Incyte, Pharmacyclics, Bristol-Myers Squibb; Consultant: Merck, Celgene, Gilead, Novartis, Pfizer

Neil Shah, MD, PhD
Professor, Department of Medicine (Hematology/Oncology)
Program Leader, Hematopoietic Malignancies Program
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, CA

Disclosures: Grant Research Support: Bristol-Myers Squibb, Ariad

David J. Straus, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY
 
 

Disclosures: Consultant: Seattle Genetics, Onco tracker 2016, Millennium (Takeda), Dava, Juno Therapeutics, Bayer 2017; Speakers’ Bureau: Roche China

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By